Month: May 2025

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) — Mercer International Inc. (“Mercer” or the “Company”) (Nasdaq: MERC), a global forest products company, today released its 2024 Sustainability Report, Fit for Future: Transition and Transformation. The report outlines, among other things, the Company’s progress towards its 2030 sustainability goals. Juan Carlos Bueno, President and CEO, stated: “In 2024, we applied the same operational discipline to our sustainability efforts that we bring to all areas of our business. We focused on where Mercer can make the most meaningful contribution—reducing emissions at the source, improving resource efficiency, and advancing renewable bioproducts. These steps reflect our learning and commitment to a long-term, practical impact that we believe will add value to our overall business.” Bill Adams, Chief...

The final short form prospectus is accessible through SEDAR+ NOT FOR DISTRIBUTION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW CALGARY, Alberta, May 27, 2025 (GLOBE NEWSWIRE) — Alaris Equity Partners Income Trust (“Alaris” or the “Trust“) (TSX: AD.UN) is pleased to announce today that it has filed, and obtained a receipt for, a final short form prospectus (the “Prospectus“) in each of the provinces of Canada, other than Québec, with respect to the previously announced bought deal offering of $80 million principal amount of 6.50% convertible unsecured senior debentures (the “Debentures”) through a syndicate of underwriters (the “Underwriters“) led by National Bank Financial Inc., CIBC Capital Markets and Desjardins...

Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibody Designation underscores the potential of TEV-53408, currently undergoing a Phase 2a study for the treatment of celiac disease Candidate demonstrates Teva’s commitment to bringing important new treatment options to underserved patient populationsTEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries, Ltd. (NYSE and TASE: TEVA) today announced that the US Food and Drug Administration (FDA) granted Fast Track designation for investigational TEV-53408, an anti-IL-15 antibody, for the treatment of people with celiac disease on a gluten-free diet. TEV-53408 is currently being evaluated in a Phase 2a trial to assess the efficacy and safety in adults with celiac disease. Fast Track is an FDA process designed to facilitate development...

SummaryHavila Kystruten delivered further improvements in both revenue and profitability in the first quarter of 2025. The company reported a strengthened operating result (EBITDA), primarily driven by top-line growth. In Q1 2025, Havila Kystruten generated revenues of MNOK 350, an increase of 20% from MNOK 293 in the same period last year. The growth was mainly due to a 35% increase in average cabin revenue (ACR), which rose from NOK 3,350 to NOK 4,600. Onboard sales per guest night remained stable compared to last year, despite expected growth. More challenging weather than normal resulted in cancelled excursions, thus negatively impacting onboard sales. The occupancy rate ended at 61%, down from 68% in Q1 2024. The decline was due to an unusually high occupancy last year, partly because of rebooked guests following previous cancellations,...

The board of directors of Havila Kystruten AS has today approved the financial statements and annual report for 2024, which integrates financial and sustainability reporting. The report is attached in PDF format. It summarizes the year and highlights the company’s fundamental focus on the environment and sustainability. Contacts:Chief Executive Officer: Bent Martini, +47 905 99 650Chief Financial Officer: Aleksander Røynesdal, +47 413 18 114   This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActAttachmentHKY Annual Report 2024

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 27, 2025 (GLOBE NEWSWIRE) — Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) announces that it has granted an additional 633,589 restricted share units (“RSUs”) and 330,132 stock options (“Options”) to continuing employees and consultants of Rocket Doctor Inc., the Company’s wholly-owned subsidiary (see News Release dated April 10, 2025). The Options are each exercisable for one common share of the Company at an exercise price of C$0.50 per share for a period of three years from the grant date and vest over a one-year term. The RSUs are valid for a term of three years and vest over a period of one year from the grant date. All Options and RSUs are subject to the terms...

MARKHAM, Ontario, May 27, 2025 (GLOBE NEWSWIRE) — Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today announced the results of matters voted on at its annual and special meeting of shareholders held on May 27, 2025 (the “Meeting”). The voting results for each of the matters considered at the Meeting are presented below.  The total number of common shares represented by shareholders present in person or by proxy at the Meeting was 47,282,730, representing 56.41% of the Company’s outstanding common shares. 1.    Election of Directors On a vote by ballot, the election of the following nine nominees as directors of the Company to hold office until the next annual meeting of the Company, or until their respective successors are elected or appointed, was approved. The results of the vote on this matter are set out below.Nominee Votes...

TORONTO, May 27, 2025 (GLOBE NEWSWIRE) — Captor Capital Corp. (“Captor” or the “Company”) (CSE: CPTR) is excited to announce a significant milestone in its growth strategy with the acquisition of US$500,000 in Bitcoin for treasury holdings and the issuance of unsecured convertible loan notes (the “Notes”) in the aggregate amount of US$450,000 to a European-based institutional investor (the “Noteholder”). These strategic moves reinforce Captor’s commitment to innovative financial strategies and delivering exceptional value to its shareholders. The Notes will be convertible into common shares in the capital of Captor (the “Common Shares”) at a price equal to the closing price of the Common Shares trading on the Canadian Securities Exchange (the “CSE”) on the day immediately before the earlier of May 27, 2026 (the “Maturity Date”)...